Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672803 | 0.91 | MCL1 (0.54) | MCL1KMT2AMEN1TSHRAPEX1 | |
| SCHEMBL5273001 | 0.89 | CAPN1 (0.56) | MCL1KMT2AMEN1TSHRAPEX1 | |
| SCHEMBL4093872 | 0.86 | PLK1 (0.52) | MCL1TSHRMAPK1PLK1KDM4E | |
| SCHEMBL13348987 | 0.85 | PLK1 (0.51) | MCL1KMT2AMEN1TSHRPLK1 | |
| SCHEMBL28131940 | 0.85 | TEAD1 (0.51) | KMT2AMEN1TSHRPLK1KDM4E | |
| SCHEMBL27556248 | 0.84 | MCL1 (0.60) | MCL1KMT2AMEN1TSHRAPEX1 | |
| SCHEMBL4672754 | 0.84 | MCL1 (0.65) | MCL1KMT2AMEN1TSHRAPEX1 | |
| Oxalic Acid SCHEMBL28849573 | 0.84 | ALDH1A1 (0.49) | MCL1KMT2AMEN1TSHRPLK1 | |
| SCHEMBL9393930 | 0.83 | PLK1 (0.64) | MCL1KMT2AMEN1TSHRAPEX1 | |
| SCHEMBL1443853 | 0.83 | MCL1 (0.58) | MCL1KMT2AMEN1TSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0231244-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP PLC (GB) | 1987-08-12 | — | — | EP | disclosed |
| WO-1987000525-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP P.L.C. (GB) | 1987-01-29 | — | — | WO | disclosed |
| US-4495357-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4455427-A | THROMBOXANE INHIBITORS | THE UPJOHN COMPANY (US) | 1984-06-19 | — | — | US | disclosed |
| US-4452986-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MCL1 2488/4885KMT2A 2920/4885MEN1 2054/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | MCL1 2692/4885KMT2A 1833/4885MEN1 3024/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MCL1 4778/4885KMT2A 988/4885MEN1 590/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MCL1 4778/4885KMT2A 988/4885MEN1 590/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MCL1 4778/4885KMT2A 988/4885MEN1 590/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | MCL1 2522/4885KMT2A 2410/4885MEN1 3396/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MCL1 2488/4885KMT2A 2920/4885MEN1 2054/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MCL1 2488/4885KMT2A 2920/4885MEN1 2054/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MCL1 4778/4885KMT2A 988/4885MEN1 590/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MCL1 2488/4885KMT2A 2920/4885MEN1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.